Video

Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.

      Related Videos
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Related Content
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Published: April 29th 2025 | Updated: April 29th 2025

      Ultra-low PSA responses are more prevalent with darolutamide plus ADT

      Benjamin P. Saylor
      The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Stephen J. Freedland, MD
      April 28th 2025

      Most men in EMBARK trial recover T levels following treatment suspension

      Benjamin P. Saylor
      More than 80% of patients in both groups had a full recovery of testosterone.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      April 25th 2025

      FDA clears AI-powered application for measuring prostate volume

      Benjamin P. Saylor
      Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.
      Study shows IsoPSA’s predictive ability for clinically significant prostate cancer
      April 23rd 2025

      Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

      Hannah Clarke
      "In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.
      © 2025 MJH Life Sciences

      All rights reserved.